IraJacobsonMD

PubMed

• 519 citations
  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infe...
  Paul Y. Kwo, Eric Lawitz, Jonathan McCone, Eugene R. Schiff, John M. Vierling
  Lancet. 2010-08-28
• 147 citations
  New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
  Christoph Welsch, Arun Jesudian, Stefan Zeuzem, Ira M. Jacobson
  Gut. 2012-05-01
• 28 citations
  Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
  Manal F Abdelmalek, Arun J Sanyal, Atsushi Nakajima, Brent A Neuschwander-Tetri, Zachary D Goodman
  Clinical Gastroenterology and Hepatology. 2024-01-01

Journal Articles

• Diagnosis and Management of Primary Biliary Cholangitis  
  Zobair M Younossi, Kris V Kowdley, Ira M Jacobson, Mitchell L Shiffman, Paul Kwo, Nature
• Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure  
  Ira Jacobson, MD, Hepatology
• Hepatitis C virus RNA functionally sequesters miR-122  
  Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, Nishiuchi E, Takacs CN, Catanese MT, de Jong YP, Rice CM, Darnell RB, Cell, 1/12/2015
• Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed  
  Pol S, Sulkowski MS, Hassanein T, Gane EJ, Liu L, Mo H, Doehle B, Kanwar B, Brainard D, Subramanian GM, Symonds WT, McHutchison JG, Nahass RG, Bennett M, Hepatology, 1/6/2015
• Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection  
  Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Muir AJ, Reddy KR, Tam E, Ortiz-..., JAMA, 1/5/2015
• Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin  
  Feld JJ, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kul..., J Hepatol, 1/1/2015
•  
  Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, B..., Liver Int, 1/1/2015
• Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus  
  Yoshida EM, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, ..., Hepatology, 1/1/2015
• Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin  
  Zeuzem S, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot..., N Engl J Med, 1/24/2014
• Daclatasvir plus sofosbuvir for HCV infection  
  Sulkowski MS, Nelson DR, N Engl J Med, 1/17/2014
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection  
  Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Subramanian GM, Ding X, Mo H, Ya..., N Engl J Med, 1/15/2014
• Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribav...  
  Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B,..., Lancet, 1/15/2014
• Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials  
  Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brain..., Clin Infect Dis, 1/15/2014
• Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C  
  Lawitz E, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Freilich B, Rodrig..., Antivir Ther, 1/8/2014
• Antisense therapy for hepatitis C virus infection  
  with de Jong YP, J Hepatol, 1/1/2014
• Emerging therapies for the treatment of hepatitis C  
  Lange CM, Rice CM, Zeuzem S, EMBO Mol Med, 1/1/2014
•  
  Gordon SC, Reddy KR, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ, J Clin Gastroenterol, 1/1/2014
• VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection  
  Di Bisceglie AM, Sulkowski M, Gane E, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ, Eur J Gastroenterol Hepatol, 1/1/2014
• Telaprevir-based treatment effects on hepatitis C virus in liver and blood  
  Talal AH, Dimova RB, Zhang EZ, Jiang M, Penney MS, Sullivan JC, Botfield MC, Chakilam A, Sawant R, Cervini CM, Zeremski M, Kwong AD, Hepatology, 1/1/2014
• Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens  
  Younossi ZM, Stepanova M, Nader F, Gane E, Nelson D, Lawitz E, Hunt SL, Hepatology, 1/1/2014
• A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection  
  Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jeffers L, Kowdley KV, Lawitz E, Lueth S..., J Hepatol, 1/1/2014
• All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study  
  Manns M, Pol S, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, ..., Lancet, 1/1/2014
• Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C  
  with Kumar S, J Hepatol, 1/1/2014
• Advances in the treatment of Hepatitis C virus infection from the Liver Meeting  
  Jacobson IM, Gastroenterology & Hepatology, 1/1/2014
• Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options  
  Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennettt M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, M..., N Engl J Med, 1/16/2013
• Join now to see all

Books/Book Chapters

• Chronic Hepatitis C Virus: Advances in treatment, promise for the future 
  Chapter: Immune modulators and other agents 
  Page 131 - 148with Charles EDEditors: Shiffman ML.Springer, New York2012
• Hepatitis C direct acting antivirals: Clinics in Liver Disease: The New Standard of Care 
  Chapter: Telaprevir user’s guide 
  Page 555 - 571with Liapakis A2011
• Clinics in Liver Disease: Hepatobiliary Manifestations of Diseases Involving other Organ Systems 
  Chapter: Cardiovascular disease and the liver 
  Page 1 - 20with Weisberg ISEditors: Hu Ke-Qin.2011
• Clinical Dilemmas in Viral Liver Disease 
  Chapter: Rethinking the inactive carrier state: management of patients with low-replicative HBeAg-negative chronic hepatitis B and normal liver enzymes 
  Page 129 - 134with Weisberg ISEditors: Forster GR.Wiley-Blackwell2010
• Liver under Constant Attack-From Fat to Viruses 
  Chapter: Hepatitis C Therapy 
  Page 22 - 26Jacobson IMEditors: Day CP & Galle PR.2008
• Clinics in Liver Disease: Chronic Hepatitis B 
  Jacobson IMElsevier Saunders2007
• Schiff’s Diseases of the Liver 
  Chapter: Imaging 
  Page 83 - 126Ahmed F, Coll DEditors: Schiff ER, Sorrell MF, Maddrey WC.Lippincott, Williams, and Wilkins, PhiladelphiaEdition 10th,2007
• Management Issues in Hepatitis C Infection 
  Chapter: Evaluation of suitability for therapy 
  Jacobson IMEditors: McHutchison, JG.Science Press Limited2004
• Handbook of Liver Disease 
  Chapter: Disease of the bile ducts 
  Page 431 - 445with Purow DEditors: Friedman LS, Keeffe EB.Churchill LivingstoneEdition 2nd,2004
• Atlas of the Liver 
  Chapter: Hepatitis C 
  Page 117 - 143with Ahmed FEditors: Maddrey WC, Feldman M.Current Medicine, Philadelphia2003
• Schiff’s Diseases of the Liver 
  Chapter: Imaging overview 
  Page 281 - 286Jacobson IMEditors: Schiff ER, Sorrell MF, Maddrey WC.Lippincott, Williams and Wilkins, PhiladelphiaEdition 9th,2003
• Principles of Diabetes Mellitus 
  Chapter: Gastrointestinal manifestations of diabetes 
  Page 439 - 458with Frissora CLEditors: Poretsky L.Kluwer, Boston2002
• Gastrointestinal Oncology: Principles and Practice 
  Chapter: Hepatocellular cancer: Screening, surveillance, and prevention 
  Page 559 - 568with Russo MWEditors: Kelsen DP, et al.Williams and Wilkins, Philadelphia2002
• Clinical Practice of Gastroenterology 
  Chapter: Endoscopic management of malignant biliary obstruction 
  with Spivak JEditors: Brandt LJ.Churchill Livingston1999
• Handbook of Liver Disease 
  Chapter: Diseases of the bile ducts 
  Page 465 - 480with Channapragada SrinivasEditors: Friedman LS, Keeffe EB.Churchill Livingstone, Edinburgh1998
• ERCP and its Applications 
  Chapter: The role ERCP before laparoscopic cholecystectomy 
  Page 95 - 104Jacobson IMEditors: Jacobson IM.Lippincott, Philadelphia1998
• ERCP and its Applications 
  Jacobson IMLippincott-Raven, Philadelphia1998
• Current Diagnosis and Treatment in Gastroenterology 
  Chapter: Gallstones 
  Page 668 - 678Jacobson IMEditors: Grendell JH, McQuaid KR, Friedman SL.Appleton and Lange, Stamford1996
• Surgical Intensive Care 
  Chapter: Fulminant hepatic failure 
  Page 801 - 818Jacobson IMEditors: Barie PS, Shires GT.Little, Brown and Co., Boston1993
• In The New Book of Knowledge: Health and Medicine Annual 
  Chapter: Liver 
  Page 285 - 286Jacobson IMGrolier1992
• Current Diagnosis 8 
  Chapter: Disorders of the gallbladder and bile ducts 
  Page 745 - 751with Nestler JLEditors: Conn R.Saunders, Philadelphia1991
• Gastrointestinal diseases in the elderly 
  Chapter: Biliary and pancreatic disease in the elderly 
  Page 433 - 458with Ingber SEditors: Friedman LS.1990
• ERCP: Diagnostic and Therapeutic Applications 
  Jacobson IMElsevier, New York1989
• ERCP: Diagnostic and Therapeutic Applications 
  Chapter: Endoscopic sphincterotomy in patients with intact gallbladders 
  Page 127 - 138with Barie PSEditors: Jacobson IM.Elsevier, New York1989
• Hepatology 
  Chapter: Diseases of the gallbladder 
  Page 1532 - 1546with Barie PSEditors: Zakim D, Boyer T.Saunders, PhiladelphiaEdition 2nd,1989
• Join now to see all

Abstracts/Posters

• Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1) a phase 3, random...
  Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beaumont-Ma..., Lancet, 1/3/2014
• Sapphire II: Phase 3 Placebo controlled study of Interferon-free, 12-week regimen of ABT-450/R/ABT-267 ABT-333. And Ribavirin treatment-experienced adults with Hepatit...
  Zeuzem S, Baykal T, Marinho R.T, Poordad F., Bourliere M, Sulkowski M, Wedemeyer H., Tam E., Desmond P., Jensen D., Di Bisceglie A.M., Varunok P., Hassanein T, Xiong J..., Journal of Hepatology, 1/1/2014
• Safety and efficacy of MK-5172 plus Peginterferon Alfa-2b and Rivacirin (PR) in cirrhotic and non-cirrhotic treatment-naïve patients with hepatitis C virus (HCV) genot...
  Hezode C, Bruno S, Serfaty P, Kwo A, Zhou A, Gilbert C, Hwang P, Wahl J, Robertson M.N., Mobashery N, Journal of Hepatology, 1/1/2014
• Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naïve patients (COSMOS Study): primary endpoint (SVR12) results in p...
  Lawitz E, Ghalib R, Rodriguez-Torres M, Younossi Z.M., Corregidor A, Sulkowski M.S., DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim J.K., Pockros P.J., Fevery B, L..., Journal of Hepatology, 1/1/2014
• Efficacy and safety of Daclatasvir in combination with Asunaprevir (DCV + ASV) in cirrhotic and non-cirrhotic patients with HCV genotype 1B: results of the Hallmark du...
  Kao J.H., Heo J, Yoffe B, Sievert W, Bessone F, Pent C.Y. Roberts S, Yoon K.T., Kopit J, Linaberry M, Noviello S, Hughes E, Manns M, Journal of Hepatology, 1/1/2014
• Once-daily Simeprevir (TMC435) plus Sofosbuvir (GS-7977) with or without Ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS Study subgroup ana...
  Sulkowski M, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Fevery B, Callewaert K, Symonds W, De La Rosa G, Picchio G, Ouwerkerk-Mahadevan S, Lambrecht T, La..., Journal of Hepatology, 1/1/2014
• Successful retreatment with Sofosbuvir of HCV genotype-1 infected patients who failed prior therapy with Peginterferon + Ribavirin plus 1 or 2 additional direct-acting...
  Pol S, Sulkowski M, Hassanein T, Gane E, Liyun N, Ho H, Kanwar B, Brainard D, Subramanian M, Symonds W.T., McHutchison J.G. Bennett M, Journal of Hepatology, 1/1/2014
• Independent predictors of patient-reported outcomes (PROS) and quality of life (QOL) in chronic Hepatitis C patients receiving Interferon (INF)-free versus INF-contain...
  Younossi Z.M., Stepanova M, Nader F, Nelson D, Lawitz E, Gane E, Hunt S.L., Journal of Hepatology, 1/1/2014
• linical impact of an internet-based tool to help guide timing of HCV therapy
  Schulz J, Kwo P.Y., Muir A.J., Terrault N, King E, Sulkowski M.S., Journal of Hepatology, 1/1/2014
• Patient-reported outcomes (PROS) in chronic Hepatitis C patients with cirrhosis treated with Sofosbuvir (SOF) containing regimens
  Younossi Z.M., Stepanova M, Nader F, Nelson D, Lawitz E, Gane E, Hunt S.L., Journal of Hepatology, 1/1/2014
• Comparisons of populations in Faldaprevir phase III studies based on Pegylated Interferon a-2a and Ribavirin-predicted responsiveness and impact on achieving SVR12
  Ferenci P, Jensen D.M., Dietrich D, Romero-Gomez M, Foster G.R., Asselah T, Cooper C, Tural C, Streinu-Cercel A, Ryder S, Puoti M, Tam E, Calleja J.L., Nunez M, Quins..., Journal of Hepatology, 1/1/2014
• Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve European patients in the Quest-1 and Quest-2 phas...
  Foster G.R., Dore G.J. Fried M, Manns M, Marcellin P, Poordad F, Affonso de Araujo E.S. Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, B..., Journal of Hepatology, 1/1/2014
• Effect of HCV genotype-1 subtype on response to Faldaprevir plus Pegylated Interferon a-2a and Ribavirin in treatment-naïve patients: pooled data from phase III trials
  Jensen D.M., Dietrich D, Sarrazin C, Foster G.R., Yoshida E.M., Nelson M, Ingiliz P, Soriano V, Cooper C, Stern J.O., Quinson A.M., Kukolj G, Scherer J, Drulak M, Gall..., Journal of Hepatology, 1/1/2014
• Similar adjusted SVR12 rates for HIV co-infected and HCV mono-infected patients and no dose or population (treatment-naïve / relapse) effect: pooled analysis of Faldap...
  Dietrich D, Ferenci P, Negro F, Puoti M, Rockstoh J.K. Manns M.P., Arast’eh K, Oliveira C, Dufour J.F., Zehnter E, Leen C, Bhagani S, Stern J.O., Quinson A.M., Scherer..., Journal of Hepatology, 1/1/2014
• Pharmacokinetic-response analysis of Faldaprevir in patients with chronic HCV genotype-1 infection with prior relapse
  Asselah T, Zehnter E, Agarwal K, Sakai Y, Yatshuashi H, Willems B, Writght D, Calinas F, Calleja J.L., Negro F, Stern J.O., Quinson A.M., Sha N, Dorleacq N, Schobelock M, Journal of Hepatology, 1/1/2014
• NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving Faldaprevir + Peginterferon/Ribavirin in three...
  Berger K, Sarrazin C, Ferenci P, Jensen D.M., Stern J.O., Quinson A.M., Scherer J, Kukolj G, Journal of Hepatology, 1/1/2014
• Faldaprevir efficacy in HCV genotype-1 infected patients in four phase 3 trials: analysis by NS3 baseline polymorphisms, genotype-1 subtype and genotype-1A clades
  Berger K, Sarrazin C, Jensen D.M., Ferenci P, Dietrich D, Stern J.O., Quinson A.M., Scherer J, Kukolj G, Journal of Hepatology, 1/1/2014
• All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION...
  Marcellin P, Mangia A, Kwo PY, Foster G, Buti M, Brau N, Muir AJ, and others, Gastroenterology, 1/1/2014
• Jensen DM, Dieterich DT, Sarrazin C, Foster G, Yoshida EM, Nelson M, Ingiliz P, and others, Gastroenterology, 1/1/2014
• Faldaprevir Efficacy in HCV Genotype-1-Infected Patients in Four Phase III Trials: Analysis by Ns3 Baseline Polymorphisms, Genotype-1 Subtype and Genotype-1A Clades
  Berger K, Sarrazin C, Jensen DM, Ferenci P, Dieterich DT, Stern JO, Quinson A, and others, Gastroenterology, 1/1/2014
• Similar Adjusted Svr12 Rates for HIV Co-Infected and HCV Mono-Infected Patients and No Dose or Population (Treatment-Naïve/Relapser) Effect: Pooled Analysis of Faldapr...
  Dieterich DT, Ferenci P, Negro F, Puoti M, Rockstroh JK, Manns MP, Arastéh K, and others, Gastroenterology, 1/1/2014
• Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors
  Christensen C, Conway B, Ma J, Bekele N, Brainard DM, Symonds WT, McHutchison JG, and others, Gastroenterology, 1/1/2014
• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults with...
  Zeuzem S, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski M, Wedemeyer H, and others, Gastroenterology, 1/1/2014
• Ns3 Q80k Did Not Impact Efficacy or Treatment-Emergent Resistance Patterns in HCV Genotype-1-Infected Patients Receiving Faldaprevir Plus Pegylated Interferon/Ribaviri...
  Berger K, Sarrazin C, Ferenci P, Jensen DM, Stern JO, Quinson A, Scherer J, and others, Gastroenterology, 1/1/2014
• Successful Retreatment of HCV Genotype-1 Infected Patients Who Failed Prior Therapy With Peginterferon + Ribavirin Plus 1 or 2 Other Direct-Acting Antiviral Agents Wit...
  Sulkowski M, Hassanein T, Ni L, Mo H, Kanwar B, Brainard DM, Subramanian G.M., and others, Gastroenterology, 1/1/2014
• Join now to see all

Lectures

• Current State of the Are in HCV Therapy 
  1/1/2015
• Curren Therapy for HCV 
  Kansas City, KS - 1/1/2015
• All-Oral Therapies for HCV 
  La Jolla, CA - 1/1/2015
• HCV: Treat for Cure at Any Cost 
  La Jolla, CA - 1/1/2015
• The HCV Pipeline 
  New York, NY, 2014; Dallas TX, 2014 - 1/9/2014
• Progress in HCV Therapy 
  New York, NY - 1/1/2014
• Treatment of HCV Infection 
  1/1/2014
• Interferon-Free Therapy for Patients with Genotype 1 
  Barcelona, Spain - 1/1/2014
• Update on HCV therapies: Spring 2014 and Beyond 
  New York, NY - 1/1/2014
• Update on HCV 
  New York, NY - 1/1/2014
• Phase III Trials of INF-Free Regimens: Non-1 Genotypes 
  1/1/2014
• Hepatitis C, A revolution in Modern Medicine 
  1/1/2014
• Cirrhosis 
  1/1/2014
• Future HCV Treatments 
  1/1/2014
• Hepatitis C present management and challenges 
  Sydney Australia - 1/1/2013
• Hepatitis C: Present Management and Future Directions 
  Melbourne Australia - 1/1/2013
• Response differences between naive/ pretreated patients 
  1/1/2013
• Transplant for Alcoholic Liver Disease 
  New York, NY - 1/1/2013
• Hereditary GI Cancer Syndromes 
  New York, NY - 1/1/2013
• State of the Art Presentation Innovations in HCV Therapy 
  Big Island, HI - 1/1/2013
• Advancements in Hepatitis Therapies 
  New York, NY - 1/1/2013
• Emerging Interferon-free Therapies for HCV 
  New York, NY - 1/1/2013
• Treating Hepatitis C in 2013 
  New York, NY - 1/30/2012
• Update on HCV Therapy 
  Ontario, Canada, 2004, 2009 - 1/1/2012
• New Developments in HCV Therapy 
  1/1/2012
• Join now to see all

Other

• Update on hepatitis C virus in HIV/HCV co-infection 
  with Talal AH, National AIDS treatment advocacy program
  http://www.natap.org/2001/jun/current061101.htmwwnatap.org/2001/jun/current061101
  1/1/2001
• Advice for testing and treatment of hepatitis C 
  with Russo M, Medical Society of the State of New York
  1/1/1999
• ERCP and the pancreas 
  Jacobson IM, Clinical Advances in Gastroenterology, audiotape update program of American College of Gastroenterol
  1/1/1994